Lantern Pharma (LTRN) Tops Q2 EPS by 2c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
• Braze stock tumbles 10% on weak third quarter EPS guidance